Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
7,125
datasets available to search
ShareScore release 0.9.0
Dataset results
7,125 results for “Prostate cancer;”
Dataset for: Radiation therapy induces innate immune responses in patients treated for prostate cancers
<p><strong>Purpose </strong></p> <p>Radiation therapy (RT) is a curative therapeutic modality used to treat cancers as a single agent or in combination with surgery and chemotherapy. Advanced RT technologies enable treatment with large fraction, highly conformal, radiation doses to effect free-radical damage to cellular DNA leading to cell cycle arrest, cell death, and innate immune response stimulation.</p> <p><strong>Experimental Design </strong></p> <p>To understand systemic clinical responses after radiation exposure, high throughput proteomic and metabolomic analyses were performed on plasma obtained from cancer patients at intervals after prostate stereotactic body radiation therapy. Pathway analysis and multivariate analyses were used to delineate molecular alterations following radiation therapy and its correlation with clinical outcomes.</p> <p><strong>Results</strong></p> <p>DNA Damage Response (DDR) and cell cycle signaling increased within the first hour after treatment and returned to baseline by one month. Innate immune response signaling also increased within one hour of treatment but persisted for up to three months thereafter. Furthermore, robust immune responses and metabolite elevations, consistent with an early proinflammatory M1-mediated innate immune activation, were observed in patients in remission, whereas patients experiencing PSA-determined disease progression demonstrated less robust immune responses and M2-mediated metabolite elevations.</p> <p><strong>Conclusion/Discussion</strong></p> <p>To our knowledge, these data are the first report of longitudinal proteomic and metabolomic molecular responses in patients after radiation therapy for cancers. The data supports innate immune activation as a critical clinical response of patients receiving radiation therapy for prostate cancer. Furthermore, we propose that the observed innate immune responses may be generalized to the treatment of other cancer types, potentially informing multidisciplinary therapeutic strategies for cancer treatment.</p>
Prostate MRI clinically significant cancer
<p>This data set is part of the public development data for the <a href="http://auc23.grand-challenge.org/">2023 Automated Universal Classification Challenge</a> (AUC23). The data set concerns clinically significant prostate cancer classification on bi-parametric magnetic resonance imaging (bpMRI) and was derived from the <a href="https://pi-cai.grand-challenge.org/">Prostate Imaging: Cancer AI (PI-CAI)</a> challenge's <a href="https://zenodo.org/record/6624726#.ZGI4GXZBzIU">public training and development dataset</a> (v2.0). The data set was originally introduced and described by <a href="https://zenodo.org/record/6522364">Saha et al. (2022)</a>, and no images or patient information were added. Data was restructured in compliance with the <a href="https://auc23.grand-challenge.org/">AUC23</a> challenge format. The data set contains 1500 anonymized prostate bpMRI scans from 1476 patients acquired between 2012-2021 at three centers (Radboud University Medical Center, University Medical Center Groningen, Ziekenhuis Groep Twente) based in The Netherlands.</p> <p>Images are 4D tensors:</p> <ul> <li>0: 3D Axial T2-weighted imaging (T2W)</li> <li>1: 3D Axial apparent diffusion coefficient maps (ADC)</li> <li>2: 3D Axial high b-value (≥ 1000 s/mm2) diffusion-weighted imaging (HBV)</li> </ul> <p>Classification labels:</p> <ul> <li>0: Benign or indolent prostate cancer</li> <li>1: Clinically significant prostate cancer (csPCa)</li> </ul> <p>Folder structure:</p> <p>imagesTr (root folder with all patients and studies)<br> ├── 10417_1000424_0000.mha (axial T2W imaging for study 1000424)<br> ├── 10417_1000424_0001.mha (axial ADC imaging for study 1000424)<br> ├── 10417_1000424_0002.mha (axial HBV imaging for study 1000424)<br> ├── ...<br> ├── 11251_1001274_0000.mha (axial T2W imaging for study 1001274)<br> ├── 11251_1001274_0001.mha (axial ADC imaging for study 1001274)<br> ├── 11251_1001274_0002.mha (axial HBV imaging for study 1001274)<br> ├── ...</p> <p> </p> <p>Please cite the following article if you are using the <a href="https://zenodo.org/record/6522364">PI-CAI: Public Training and Development Dataset</a>:</p> <pre><code>A. Saha, J. J. Twilt, J. S. Bosma, B. van Ginneken, D. Yakar, M. Elschot, J. Veltman, J. J. Fütterer, M. de Rooij, H. Huisman, "Artificial Intelligence and Radiologists at Prostate Cancer Detection in MRI: The PI-CAI Challenge (Study Protocol)", DOI: 10.5281/zenodo.6522364 </code></pre> <p> </p>
CTC identification and characterization in prostate cancer using K/V protocol and imaging flow cytometry - part 2
<p>This project aimed to identify and characterize circulating tumor cells (CTCs) in peripheral blood of 33 prostate cancer patients. Fraction of peripheral blood mononuclear cells putatively containing CTCs was isolated using density gradient centrifugation. Pan-keratin/vimentin/CD45/CD31/DAPI immunofluorescent staining was performer and DAPI+ or DAPI+CD45/CD31- objects were collected using Amnis® ImageStream®XMk II, Cytek® Biosciences, Inc (lasers: 405 nm, 488 nm, 642 nm, magnification 40x, slow speed flow).</p>
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
ClinicalTrials.gov study NCT04915508. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients
ClinicalTrials.gov study NCT02853097. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Prostate Cancer Patient Management With 18F-DCFPyL PET/CT
ClinicalTrials.gov study NCT03459820. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Community-Based Health Coach for Access to Germline Genetic Testing Among African American Men With Prostate Cancer
ClinicalTrials.gov study NCT04763980. IPD Sharing: NO. Countries: 1. Publications: 0.
PRORAD-5 PROstate RADiation in 5 Fractions: Phase Ib Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer
ClinicalTrials.gov study NCT06369246. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
ClinicalTrials.gov study NCT06660862. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A QT/QTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer
ClinicalTrials.gov study NCT00910754. IPD Sharing: Not stated. Countries: 2. Publications: 0.
Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer
ClinicalTrials.gov study NCT00036556. IPD Sharing: Not stated. Countries: 17. Publications: 0.
Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants
ClinicalTrials.gov study NCT01497431. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer
ClinicalTrials.gov study NCT00005028. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Clinical Study of Fasudil Hydrochloride and PD1 Inhibitor Combined With Androgen Deprivation in Neoadjuvant Therapy of Prostate Cancer
ClinicalTrials.gov study NCT06861192. IPD Sharing: NO. Countries: 1. Publications: 0.
Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First)
ClinicalTrials.gov study NCT04332744. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy
ClinicalTrials.gov study NCT06085664. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Soy Bread Diet in Improving Immune Function in Participants With Prostate Cancer
ClinicalTrials.gov study NCT03654638. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer
ClinicalTrials.gov study NCT03976843. IPD Sharing: YES. Countries: 1. Publications: 0.
PSMA PET Scan and mpMRI for Prostate Cancer Detection
ClinicalTrials.gov study NCT05820724. IPD Sharing: NO. Countries: 1. Publications: 0.
An Open Label Prostate Cancer Study in Japanese Patients
ClinicalTrials.gov study NCT01351688. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.